Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dabrafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF known ✓ | P15056 | 20/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 5/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ULK1 | O75385 | 1/20 | 1.00 |
| ▸ | ERN1 | O75460 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dabrafenib SCHEMBL29350038 | 1.00 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29353365 | 1.00 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL13739419 | 0.99 | BRAF (0.98) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29352214 | 0.97 | BRAF (0.95) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL1127269 | 0.97 | BRAF (0.95) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL14733912 | 0.95 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL21425052 | 0.95 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2193062 | 0.95 | BRAF (0.90) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL14733909 | 0.94 | BRAF (0.89) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL2191986 | 0.92 | BRAF (0.85) | BRAFNR1I2PLK4EPHB6RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 737 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| EP-4159205-B1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2024-02-14 | — | — | EP | claimed |
| EP-2786750-B2 | AGENT FOR REDUCING ADVERSE SIDE EFFECTS OF KINASE INHIBITOR | EA PHARMA CO LTD (JP) | 2023-06-28 | — | — | EP | claimed |
| EP-4159205-A1 | NOVEL PHARMACEUTICAL COMPOSITION | Novartis AG (CH) | 2023-04-05 | — | — | EP | claimed |
| US-20230090389-A1 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, AN ERK INHIBITOR AND A SHP2 INHIBITOR | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | claimed |
| EP-4110341-A2 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, AN ERK INHIBITOR AND A RAF INHIBITOR | Novartis AG (CH) | 2023-01-04 | — | — | EP | claimed |
| EP-4110338-A1 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, AN ERK INHIBITOR AND A SHP2 INHIBITOR | Novartis AG (CH) | 2023-01-04 | — | — | EP | claimed |
| WO-2022259157-A1 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, TRAMETINIB AND A SHP2 INHIBITOR | NOVARTIS AG (CH) | 2022-12-15 | — | — | WO | claimed |
| US-11504333-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | claimed |
| CN-115297862-A | Triple pharmaceutical combination comprising dabrafenib, an ERK inhibitor and an SHP2 inhibitor | 诺华股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| EP-2485594-A1 | COMBINATION | GlaxoSmithKline LLC (US) | 2012-08-15 | — | — | EP | claimed |
| US-20120202822-A1 | COMBINATION | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | claimed |
| US-20120202835-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-08-09 | — | — | US | claimed |
| US-20120196886-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-08-02 | — | — | US | claimed |
| WO-2011046894-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-04-21 | — | — | WO | claimed |
| WO-2011044415-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-04-14 | — | — | WO | claimed |
| WO-2011044414-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-04-14 | — | — | WO | claimed |
| EP-2282636-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-02-16 | — | — | EP | claimed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | claimed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202822-A1 | COMBINATION | PIK3CA, BRAF, PIK3CD | BRAF 2/4885NR1I2 4414/4885PLK4 236/4885 |
| US-20120202835-A1 | COMBINATION | PAICS, FOLH1, DHFR | BRAF 939/4885NR1I2 3783/4885PLK4 3643/4885 |
| US-11504333-B2 | Pharmaceutical composition | SRMS, PFAS, DCPS | BRAF 3225/4885NR1I2 3738/4885PLK4 2571/4885 |
| US-20230090389-A1 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, AN ERK INHIBITOR AND A SHP2 INHIBITOR | DUSP2, PTPN1, PTPN6 | BRAF 23/4885NR1I2 2142/4885PLK4 2293/4885 |
| US-20120196886-A1 | COMBINATION | PAICS, FOLH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | BRAF 564/4885NR1I2 3378/4885PLK4 3123/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885NR1I2 886/4885PLK4 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.